European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
European equities traded in the US as American depositary receipts opened the week slightly higher Monday morning, rising 0.12% to 1,429.79 on the S&P Europe Select ADR Index. From continental Europe,
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c
Adaptimmune Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 158.62% Mizuho $9 → $3 Maintains Buy 08/10/2023 -13.79% Barclays $2 → $1 Maintains Underweight
Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating
Adaptimmune Therapeutics (ADAP) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $1 to $4.
Express News | Adaptimmune Therapeutics PLC : Mizuho Cuts Target Price to $3 From $9
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta
Analysts Conflicted on These Healthcare Names: Fortress Biotech (FBIO), GoodRx Holdings (GDRX) and Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics | 10-Q: Quarterly report
TD Cowen Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)
Earnings Call Summary | Adaptimmune Therapeutics(ADAP.US) Q1 2024 Earnings Conference
The following is a summary of the Adaptimmune Therapeutics Plc (ADAP) Q1 2024 Earnings Call Transcript:Financial Performance:Adaptimmune has secured up to $125 million in debt financing with Hercules
Adaptimmune Therapeutics Plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $5
Express News | Adaptimmune Therapeutics PLC -Believes Existing Cash, Cash Equivalents and Marketable Securities Will Fund Co’s Current Operations Into Late 2025
Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Posts Q1 Revenue $5.7M, Vs. Street Est of $17.1M
07:34 AM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Posts Q1 Revenue $5.7M, vs. Street Est of $17.1M
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing inf
Express News | Adaptimmune Therapeutics-First Tranche of $25 Mln Available Upon Closing; Co Will Be Eligible to Draw Additional $25 Mln Subject to Afami-Cel Approval
Express News | Adaptimmune Therapeutics PLC - Has Entered Into $125 Mln Five-Year, Term Loan Facility With Hercules Capital, Inc
Express News | Adaptimmune Therapeutics PLC - Secures up to $125 Million Debt Financing With Hercules Capital
Adaptimmune Secures up to $125 Million Debt Financing With Hercules Capital
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approvalPhiladelphia, Pennsylvania and Oxford, United Kindgom--